The short version of GHRH receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-14 and is reviewed periodically as new material appears.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
== Medical uses == Injectable fillers are widely used in cosmetics for soft tissue augmentation and facial rejuvenation. Their primary clinical applications include the correction of facial wrinkles and folds, restoration of age-related volume loss, and the enhancement of facial contours such as the lips, cheeks, and jawline. Hyaluronic acid-based fillers are commonly used for superficial and mid-dermal injections to treat fine lines and improve skin hydration, while more robust fillers are injected into deeper tissue layers to correct severe wrinkles and provide structural support. Biodegradable fillers, such as poly(lactic acid), can stimulate collagen production, contributing to longer-term volume effects. Injectable hydrogel-based fillers have been investigated for a wide range of medical applications due to their biocompatibility, injectability, and ability to form three-dimensional networks in situ. In wound healing, these materials provide a moist environment, act as barriers against infection, and conform to irregular tissue defects, thereby promoting tissue regeneration. They are also used to prevent post-operative adhesions by acting as physical barriers that separate tissues during healing, reducing fibrotic attachment. In hemostasis, injectable hydrogels can rapidly solidify at bleeding sites and adhere to tissues, enabling effective control of hemorrhage.
The mechanism of action is explained below: a) Application of acid to dentin will result in partial/total removal of smear layer and demineralization of the dentin. b) Acid will demineralize the intertubular and peritubular dentin, and then open the dentinal tubules while exposing the collagen fibres, hence increasing the microporosity of intertubular dentin. c) Dentin will be demineralized by up to approximately 7.5 μmeter, depending on the type of acid used, time of application and concentration. d) Primer system is designed to increase critical surface tension of dentin, which gets decreased after etching of acid. e) Bonding mechanism is when:
== External links == Pale Saints discography at Discogs Pale Saints at IMDb Big Beautiful Bluebottle – Ian Masters's current project. Kuchen – Meriel Barham's current project. Rykarda Parasol – one of Colleen Browne's former bands.
== History == Secukinumab was discovered and developed by Novartis using developmental name AIN457, and the first publication was a Phase I trial published in 2010. In January 2015, secukinumab was approved in the United States and in the European Union to treat adults with moderate-to-severe plaque psoriasis. It is the first IL17A inhibiting drug ever approved. In January 2016, the FDA approved it to treat adults with ankylosing spondylitis, and psoriatic arthritis and in February 2018, a label update was approved to include the treatment for moderate-to-severe scalp psoriasis.
Sources: en.wikipedia.org
Most industries are located in the industrial-port area north of the estuary and east of the city of Le Havre. The largest industrial employer (2,400 employees) of the Le Havre region is the Renault public company in the commune of Sandouville. The second important sector for the industrial zone is petrochemicals. The Le Havre region has more than a third of French refining capacity. It provides about 50% of the production of basic plastics and 80% of additives and oils with more than 3,500 researchers working in private and public laboratories. Large firms in the chemical industry are mainly in the communes of Le Havre (Millenium Chemicals Le Havre), Montivilliers (TotalEnergies, Yara, Chevron Oronite SA, Lanxess, etc.) and Sandouville (Goodyear Chemicals Europe). A total of 28 industrial establishments manufacture plastics in the Le Havre area many of which are classed as SECESO. There are several firms in the aerospace industry: SAFRAN Nacelles, a supplier to Airbus, Boeing and other commercial air-framers, making jet engine nacelles and thrust reversers, is located in Harfleur and employs 1,200 people from the Le Havre area. Finally, Dresser-Rand SA manufactures equipment for the oil and gas industry and employs about 700 people. In the energy field, the EDF thermal power plant of Le Havre has an installed capacity of 1,450MW and operates using coal with 357 employees. The AREVA group announced the opening of a factory for building wind turbines: installed in the port of Le Havre, it should create some 1,800 jobs.
"p53 Knowledgebase". Lane Group at the Institute of Molecular and Cell Biology (IMCB), Singapore. Archived from the original on 2006-01-03. Retrieved 2008-04-06. GeneReviews/NCBI/NIH/UW entry on Li-Fraumeni Syndrome TUMOR PROTEIN p53 @ OMIM p53 restoration of function p53 @ The Atlas of Genetics and Cytogenetics in Oncology and Haematology TP53 Gene @ GeneCards p53 News provided by insciences organisation Goodsel DS (2002-07-01). "p53 Tumor Suppressor". Molecule of the Month. RCSB Protein Data Bank. Retrieved 2008-04-06. Soussi T. "p53 Web Site". Retrieved 2008-04-06. Living LFS A non-profit Li-Fraumeni Syndrome patient support organization The George Pantziarka TP53 Trust A support group from the UK for people with Li-Fraumeni Syndrome or other TP53-related disorders IARC TP53 Somatic Mutations database maintained at IARC, Lyon, by Magali Olivier PDBe-KB provides an overview of all the structure information available in the PDB for Human P53. scientific animation conformational changes of p53 upon binding to DNA
Perfluoroalkyl carboxylic acids (PFCAs), such as trifluoroacetic acid (TFA) Perfluorosulfonic acids (PFSAs), such as perfluorooctanesulfonic acid (PFOS) Precursors to PFCAs, such as fluorotelomers, including as fluorotelomer alcohols (FTOHs) Precursors to PFSAs, such as perfluorobutane sulfonamide (H-FBSA), perfluorooctanesulfonamide (PFOSA), perfluorobutanesulfonyl fluoride (PFOSB) or perfluorooctanesulfonyl fluoride (PFOSF) Fluoropolymers such as polytetrafluoroethylene (PTFE, aka Teflon)
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.